Abstract
The signaling enzyme Phospholipase D (PLD) has been implicated in numerous cell biological processes, including Ras activation, cell spreading, stress fiber formation, chemotaxis, and vesicular trafficking during neurotransmitter and hormonal release. These observations have been mostly obtained from cell culture experiments using a primary alcohol to inhibit PLD activity or by modulating endogenous expression levels of the PLD1 and PLD2 isoforms. Since modulating PLD levels can have non-specific long-term effects and alcohols have been described to cause PLD-independent deleterious effects, the identification of potent specific small molecule PLD inhibitors is an important advance for the field. In this review, I will highlight the recent identification and characterization of chemical PLD inhibitors and describe their potential therapeutic interest in the treatment of human brain diseases/disorders and cancer metastasis.
Keywords: Phospholipase D, inhibitor, cancer, immunity, cognition
Current Chemical Biology
Title: Therapeutic Potentials of Recently Identified PLD Inhibitors
Volume: 4 Issue: 3
Author(s): Nicolas Vitale
Affiliation:
Keywords: Phospholipase D, inhibitor, cancer, immunity, cognition
Abstract: The signaling enzyme Phospholipase D (PLD) has been implicated in numerous cell biological processes, including Ras activation, cell spreading, stress fiber formation, chemotaxis, and vesicular trafficking during neurotransmitter and hormonal release. These observations have been mostly obtained from cell culture experiments using a primary alcohol to inhibit PLD activity or by modulating endogenous expression levels of the PLD1 and PLD2 isoforms. Since modulating PLD levels can have non-specific long-term effects and alcohols have been described to cause PLD-independent deleterious effects, the identification of potent specific small molecule PLD inhibitors is an important advance for the field. In this review, I will highlight the recent identification and characterization of chemical PLD inhibitors and describe their potential therapeutic interest in the treatment of human brain diseases/disorders and cancer metastasis.
Export Options
About this article
Cite this article as:
Vitale Nicolas, Therapeutic Potentials of Recently Identified PLD Inhibitors, Current Chemical Biology 2010; 4 (3) . https://dx.doi.org/10.2174/2212796811004030244
DOI https://dx.doi.org/10.2174/2212796811004030244 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine Passive Smoking, Asthma and Allergy in Children
Inflammation & Allergy - Drug Targets (Discontinued) Does Piperacillin-Tazobactam Increase the Risk of Nephrotoxicity when Used with Vancomycin: A Meta-Analysis of Observational Trials
Current Drug Safety Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry The Thymus During HIV Disease: Role in Pathogenesis and in Immune Recovery
Current HIV Research Feasibility of FDG PET in Inflammatory Bowel Disease
Current Molecular Imaging (Discontinued) Medication Errors in Ambulatory Paediatric Patient Setting ‒ How Close, or Far, are we from an Error Free Process?
Infectious Disorders - Drug Targets Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis
Current Drug Targets